title: Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer.
authors.forename: Stefan
authors.initials: S
authors.lastname: Boeck
authors.forename: Sandra
authors.initials: S
authors.lastname: Geiger
authors.forename: Christoph
authors.initials: C
authors.lastname: Schulz
authors.forename: Volker
authors.initials: V
authors.lastname: Heinemann
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010956:Plasmapheresis; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D000093542:Gemcitabine
chemical_list: D007166:Immunosuppressive Agents; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine